Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede - Fierce Biotech
Why now
Thesis: Biotech IPO pipeline absorbs capital, signals risk appetite
Catalyst to watch: IPO pricing and investor demand
Main risk: Secondary valuations pressured by supply
Why it matters
A heavier biotech IPO pipeline absorbs capital and signals risk appetite but can pressure secondary valuations.
Sources
- googlenews · news.google.com · 2026-09-21 08:29 UTC